(Q38207082)

31 August 2017

New RAF kinase inhibitors in cancer therapy (English)

1 reference

31 August 2017

Juan Martin-Liberal

1

1 reference

PubMed ID

24766074

31 August 2017

James Larkin

series ordinal

2

1 reference

PubMed ID

24766074

31 August 2017

language of work or name

English

0 references

publication date

28 April 2014

1 reference

Expert Opinion on Pharmacotherapy

31 August 2017

1 reference

31 August 2017

15

1 reference

31 August 2017

9

1 reference

31 August 2017

1235-1245

1 reference

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Mammalian MAP kinase signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

From genes to drugs: targeted strategies for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Phase I/II RAF kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Evolutionary expansion of the Ras switch regulatory module in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

RAF protein-serine/threonine kinases: structure and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Mechanisms of regulating the Raf kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Prospects for MEK inhibitors for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

B-Raf and the inhibitors: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Which drug, and when, for patients with BRAF-mutant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

BRAF as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Tumor adaptation and resistance to RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Elucidating distinct roles for NF1 in melanomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.911286

10.1517/14656566.2014.911286

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24766074